Tarsus Rolls Out XDEMVY for Demodex Blepharitis

Tarsus CEO chats with DermWire on the pipeline and plans to engage dermatologists

Tarsus Pharmaceuticals, Inc. is rolling out XDEMVY, the First and Only US Food and Drug Administration-approved treatment for Demodex blepharitis.
XDEMVY is now available at pharmacies nationwide for prescription.

Bobak Azamian, MD, PhD, Chief Executive Officer, and Chairman, rang the closing bell at the Nasdaq Stock Market on Sept. 6, 2023 to mark the launch.  
Blepharitis is a common lid margin disease that is characterized by eyelid margin inflammation, redness, and ocular irritation. XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the Demodex mite infestation. 

The company is also developing forms of lotilaner to potentially treat rosacea, Lyme disease, and meibomian gland dysfunction.

“There is a natural cross-referral between dermatologists, optometrists, and ophthalmologists,“ he tells DermWire. “An ophthalmologist who is treating Demodex Blepharitis may see rosacea, and refer the patient to a dermatologist, or vice versa.”

The hope is that there will be more cross-talk between the specialists as Tarsus develop these drugs, he says.